Pulmonx Corporation Insider Trading

LUNG

Last 12 months

Insiders sold 548K and bought nothing on the open market.

8% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Jun 2025.

Net open-market

−548K

0 buys · 16 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Jun 2025

Jun 5, 2025

Get an email when LUNG's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 1	Srikanth Radhakrishnan Chief Science & Techn. Officer	SoldNo plan 4 parts	14,245	$2.26 average	32K	4.3%	Form 4
Sep 1	Glendon E. French III President and CEO	SoldNo plan 2 parts	41,882	$2.26 average	95K	2.0%	Form 4
Sep 1	Geoffrey Beran Rose Chief Commercial Officer	SoldNo plan 4 parts	7,879	$2.26 average	18K	1.7%	Form 4
Sep 1	David Aaron Lehman General Counsel	SoldNo plan 4 parts	14,334	$2.26 average	32K	3.8%	Form 4
Jun 1 – 2	Glendon E. French III President and CEO	SoldNo plan 3 parts	56,149	$1.55 average	87K	2.6%	Form 4
Jun 1	Srikanth Radhakrishnan Chief Science &Techn. Officer	SoldNo plan 4 parts	14,497	$1.54 average	22K	4.2%	Form 4
Jun 1	Geoffrey Beran Rose Chief Commercial Officer	SoldNo plan 4 parts	8,023	$1.54 average	12K	1.7%	Form 4
Jun 1	David Aaron Lehman General Counsel	SoldNo plan 4 parts	14,594	$1.54 average	22K	3.7%	Form 4
Mar 2	Srikanth Radhakrishnan Chief Science &Techn. Officer	SoldNo plan 4 parts	10,483	$1.43 average	15K	2.9%	Form 4
Mar 2	Glendon E. French III President and CEO	SoldNo plan 3 parts	67,813	$1.43 average	97K	3.1%	Form 4
Mar 2	Geoffrey Beran Rose Chief Commercial Officer	SoldNo plan 4 parts	7,732	$1.43 average	11K	1.6%	Form 4
Mar 2	David Aaron Lehman General Counsel	SoldNo plan 4 parts	12,237	$1.43 average	17K	3.0%	Form 4
Dec 8, 2025	Daniel P Florin Director	Sold10b5-1 plan	23,321	$1.99	46K	20%	Form 4
Dec 1, 2025	Glendon E. French III President and CEO	SoldNo plan 2 parts	8,805	$1.57 average	14K	0.4%	Form 4
Dec 1, 2025	Geoffrey Beran Rose Chief Commercial Officer	SoldNo plan 4 parts	6,322	$1.57 average	10K	1.7%	Form 4
Dec 1, 2025	David Aaron Lehman General Counsel	SoldNo plan 4 parts	10,278	$1.57 average	16K	3.9%	Form 4
Sep 2, 2025	Steven S. Williamson President and CEO	SoldNo plan 2 parts	9,648	$1.60 average	15K	2.6%	Form 4
Sep 2, 2025	Mehul Joshi Chief Financial Officer & PAO	SoldNo plan 2 parts	7,936	$1.60 average	13K	3.7%	Form 4
Sep 2, 2025	Geoffrey Beran Rose Chief Commercial Officer	SoldNo plan 4 parts	6,543	$1.60 average	10K	1.7%	Form 4
Sep 2, 2025	David Aaron Lehman General Counsel	SoldNo plan 4 parts	9,769	$1.60 average	16K	3.6%	Form 4
Jun 12, 2025	Richard Ferrari Director	SoldNo plan	8,000	$3.16	25K	8.4%	Form 4
Jun 5, 2025	Daniel P Florin Director	Bought	23,321	$3.06	71K	25%	Form 4
Jun 2, 2025	Steven S. Williamson President and CEO	SoldNo plan 2 parts	9,923	$3.13 average	31K	2.6%	Form 4
Jun 2, 2025	Mehul Joshi Chief Financial Officer & PAO	SoldNo plan 2 parts	8,061	$3.13 average	25K	3.6%	Form 4
Jun 2, 2025	Geoffrey Beran Rose Chief Commercial Officer	SoldNo plan 5 parts	6,947	$3.13 average	22K	1.8%	Form 4
Jun 2, 2025	David Aaron Lehman General Counsel	SoldNo plan 5 parts	10,457	$3.13 average	33K	3.7%	Form 4
Mar 20, 2025	Glendon E. French III Director	Sold10b5-1 plan	20,000	$7.85	157K	2.0%	Form 4
Mar 3, 2025	Mehul Joshi Chief Financial Officer & PAO	SoldNo plan	14,384	$7.12	102K	6.1%	Form 4
Mar 3, 2025	Steven S. Williamson President and CEO	SoldNo plan	27,689	$7.14	198K	6.9%	Form 4
Mar 3, 2025	David Aaron Lehman General Counsel	Sold10b5-1 plan 5 parts	22,355	$7.65 average	171K	7.3%	Form 4
Mar 3, 2025	Geoffrey Beran Rose Chief Commercial Officer	SoldNo plan 4 parts	5,779	$7.13 average	41K	1.4%	Form 4
Feb 20, 2025	Glendon E. French III Director	Sold10b5-1 plan 2 parts	55,453	$8.28 average	459K	5.2%	Form 4
Jan 16, 2025 – Jan 17, 2025	Glendon E. French III Director	Sold10b5-1 plan 2 parts	4,547	$6.52 average	30K	0.4%	Form 4
Dec 2, 2024	Geoffrey Beran Rose Chief Commercial Officer	SoldNo plan 4 parts	4,376	$6.18 average	27K	1.5%	Form 4
Dec 2, 2024	David Aaron Lehman General Counsel	SoldNo plan 4 parts	5,497	$6.19 average	34K	2.7%	Form 4
Nov 22, 2024	Glendon E. French III Director	Sold10b5-1 plan	20,000	$6.63	133K	1.8%	Form 4

Sep 1No plan
Srikanth Radhakrishnan
Chief Science & Techn. Officer · sold 14,245 at avg $2.26
32K
4.3% of stake
Sep 1No plan
Glendon E. French III
President and CEO · sold 41,882 at avg $2.26
95K
2.0% of stake
Sep 1No plan
Geoffrey Beran Rose
Chief Commercial Officer · sold 7,879 at avg $2.26
18K
1.7% of stake
Sep 1No plan
David Aaron Lehman
General Counsel · sold 14,334 at avg $2.26
32K
3.8% of stake
Jun 1 – 2No plan
Glendon E. French III
President and CEO · sold 56,149 at avg $1.55
87K
2.6% of stake
Jun 1No plan
Srikanth Radhakrishnan
Chief Science &Techn. Officer · sold 14,497 at avg $1.54
22K
4.2% of stake
Jun 1No plan
Geoffrey Beran Rose
Chief Commercial Officer · sold 8,023 at avg $1.54
12K
1.7% of stake
Jun 1No plan
David Aaron Lehman
General Counsel · sold 14,594 at avg $1.54
22K
3.7% of stake
Mar 2No plan
Srikanth Radhakrishnan
Chief Science &Techn. Officer · sold 10,483 at avg $1.43
15K
2.9% of stake
Mar 2No plan
Glendon E. French III
President and CEO · sold 67,813 at avg $1.43
97K
3.1% of stake
Mar 2No plan
Geoffrey Beran Rose
Chief Commercial Officer · sold 7,732 at avg $1.43
11K
1.6% of stake
Mar 2No plan
David Aaron Lehman
General Counsel · sold 12,237 at avg $1.43
17K
3.0% of stake
Dec 8, 202510b5-1 plan
Daniel P Florin
Director · sold 23,321 at $1.99
46K
20% of stake
Dec 1, 2025No plan
Glendon E. French III
President and CEO · sold 8,805 at avg $1.57
14K
0.4% of stake
Dec 1, 2025No plan
Geoffrey Beran Rose
Chief Commercial Officer · sold 6,322 at avg $1.57
10K
1.7% of stake
Dec 1, 2025No plan
David Aaron Lehman
General Counsel · sold 10,278 at avg $1.57
16K
3.9% of stake
Sep 2, 2025No plan
Steven S. Williamson
President and CEO · sold 9,648 at avg $1.60
15K
2.6% of stake
Sep 2, 2025No plan
Mehul Joshi
Chief Financial Officer & PAO · sold 7,936 at avg $1.60
13K
3.7% of stake
Sep 2, 2025No plan
Geoffrey Beran Rose
Chief Commercial Officer · sold 6,543 at avg $1.60
10K
1.7% of stake
Sep 2, 2025No plan
David Aaron Lehman
General Counsel · sold 9,769 at avg $1.60
16K
3.6% of stake
Jun 12, 2025No plan
Richard Ferrari
Director · sold 8,000 at $3.16
25K
8.4% of stake
Jun 5, 2025
Daniel P Florin
Director · bought 23,321 at $3.06
71K
25% of stake
Jun 2, 2025No plan
Steven S. Williamson
President and CEO · sold 9,923 at avg $3.13
31K
2.6% of stake
Jun 2, 2025No plan
Mehul Joshi
Chief Financial Officer & PAO · sold 8,061 at avg $3.13
25K
3.6% of stake
Jun 2, 2025No plan
Geoffrey Beran Rose
Chief Commercial Officer · sold 6,947 at avg $3.13
22K
1.8% of stake
Jun 2, 2025No plan
David Aaron Lehman
General Counsel · sold 10,457 at avg $3.13
33K
3.7% of stake
Mar 20, 202510b5-1 plan
Glendon E. French III
Director · sold 20,000 at $7.85
157K
2.0% of stake
Mar 3, 2025No plan
Mehul Joshi
Chief Financial Officer & PAO · sold 14,384 at $7.12
102K
6.1% of stake
Mar 3, 2025No plan
Steven S. Williamson
President and CEO · sold 27,689 at $7.14
198K
6.9% of stake
Mar 3, 202510b5-1 plan
David Aaron Lehman
General Counsel · sold 22,355 at avg $7.65
171K
7.3% of stake
Mar 3, 2025No plan
Geoffrey Beran Rose
Chief Commercial Officer · sold 5,779 at avg $7.13
41K
1.4% of stake
Feb 20, 202510b5-1 plan
Glendon E. French III
Director · sold 55,453 at avg $8.28
459K
5.2% of stake
Jan 16, 2025 – Jan 17, 202510b5-1 plan
Glendon E. French III
Director · sold 4,547 at avg $6.52
30K
0.4% of stake
Dec 2, 2024No plan
Geoffrey Beran Rose
Chief Commercial Officer · sold 4,376 at avg $6.18
27K
1.5% of stake
Dec 2, 2024No plan
David Aaron Lehman
General Counsel · sold 5,497 at avg $6.19
34K
2.7% of stake
Nov 22, 202410b5-1 plan
Glendon E. French III
Director · sold 20,000 at $6.63
133K
1.8% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch LUNG, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with LUNG

CompareIntrinsic value

IRMDIradimed Corp

$88.58+9.21%80

SGHTSight Sciences, Inc.

$9.68+2.76%33

DCTHDelcath Systems Inc.

$14.82+2.92%62

MHUAFMeihua International Medical Technologies Co., Ltd.

$6.30-8.16%59

TELATela Bio Inc.

$0.87+8.72%30

PDEXPro-Dex Inc.

$63.44+5.31%86

RCELAvita Medical Inc.

$16.32+6.46%30

NPCENeuroPace Inc.

$13.34+8.37%30

Held by ETFs

LUNG is in 1 US ETF. The largest of them, with LUNG's weight in each:

iShares Micro-Cap ETFIWC0.03%of the fund

Spot a number that looks wrong? Check it in LUNG's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LUNG

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.